SURGAR funding news – France-based SURGAR Secures €11 Million in Funding

The internal organ structures (tumors, arteries, and ducts) can be seen by the surgeon. Surgeons can operate more quickly, safely, and effectively because to technology. The objective is 20-fold increase in precision and a halving of surgical complications! Patients gain greatly from minimally invasive surgery, reduced risk of cancer recurrence and complication rates, while healthcare providers save a significant amount of money due to shorter hospital stays and more efficient operation.

Read also - La Solive funding news – French-based La Solive Secures €4 Million in a Series A Round Funding

The technology is the outcome of more than a decade of cooperation between the Pascal Institute's (Université Clermont-Auvergne, CNRS, INP Clermont-Auvergne) EnCoV team and the Clermont-Ferrand University Hospital. Thanks to the collaboration of Professors Bourdel, Bartoli, Canis, and Le Roy, who are also co-founders of the firm, SURGAR integrates artificial intelligence, computer vision, and clinical experience.

Nicolas Bourdel, CEO and founder of SURGAR, stated: "SURGAR is, above all, a human adventure and the result of long-standing collaboration. By addressing a critical need for surgeons, we are serving patients. We have just reached a decisive milestone with the CE marking of our first solution. With this funding, we are set to introduce the first-ever augmented reality solution for abdominal surgery."

The lead investor in the round was Mutuelles Impact, which is run by XAnge. Other investors included Jacques Gardette, the founder of Biocorp, Elaia Partners in collaboration with MH Innov, the corporate fund of Malakoff Humanis, and Bpifrance via its Digital Venture fund. Additionally, the business profited from the reaffirmed commitment of its previous investors, Crédit Agricole Capital Innovation and UI Investissement.

Nadja Bresous, Partner at XAnge, added: "The technology developed by SURGAR is a true demonstration of AI serving patients. The solution improves the preparation of laparoscopic surgeries, makes them more efficient, and reduces post-operative complications for patients, including limiting reoperations."

Céline Passedouet, Investment Director at Elaia, "This strategic investment marks a key step in transforming surgery in France."

With this money, SURGAR will be able to release U-SURGAR, a software specifically designed for female patients with fibroids and adenomyosis, a kind of endometriosis in the uterus, as well as complete and market L-SURGAR and K-SURGAR, which are intended to treat kidney and liver cancers, respectively.

About SURGAR

Four co-founders, Nicolas Bourdel, Adrien Bartoli, Michel Canis, and Bertrand Le Roy, were the driving forces behind the creation of the SURGAR project. Their business expands on the research team EnCoV (Endoscopy and Computer Vision). Part of the Image Guided Therapy (IGT) department of the UMR6602 Institut Pascal, which is affiliated with the CNRS, the University of Clermont Auvergne (UCA), and Clermont Auvergne INP, is this computer vision-focused team.